As of January 1, 2024, a combined 65 percent of Alzheimer’s disease drugs in clinical phase III of development were disease-modifying therapies, of which 37 percent were small molecule therapies. This statistic illustrates Alzheimer’s disease drugs in phase III of development worldwide, by mechanism of action.
Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by mechanism of action
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Alzheimer's Association. (April 24, 2024). Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by mechanism of action [Graph]. In Statista. Retrieved November 21, 2024, from https://www.statista.com/statistics/1173690/alzheimer-disease-drug-phase-iii-by-mechanism-of-action/
Alzheimer's Association. "Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by mechanism of action." Chart. April 24, 2024. Statista. Accessed November 21, 2024. https://www.statista.com/statistics/1173690/alzheimer-disease-drug-phase-iii-by-mechanism-of-action/
Alzheimer's Association. (2024). Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by mechanism of action. Statista. Statista Inc.. Accessed: November 21, 2024. https://www.statista.com/statistics/1173690/alzheimer-disease-drug-phase-iii-by-mechanism-of-action/
Alzheimer's Association. "Alzheimer’s Disease Drugs in Clinical Trial Phase Iii Worldwide as of 2024, by Mechanism of Action." Statista, Statista Inc., 24 Apr 2024, https://www.statista.com/statistics/1173690/alzheimer-disease-drug-phase-iii-by-mechanism-of-action/
Alzheimer's Association, Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by mechanism of action Statista, https://www.statista.com/statistics/1173690/alzheimer-disease-drug-phase-iii-by-mechanism-of-action/ (last visited November 21, 2024)
Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by mechanism of action [Graph], Alzheimer's Association, April 24, 2024. [Online]. Available: https://www.statista.com/statistics/1173690/alzheimer-disease-drug-phase-iii-by-mechanism-of-action/
